High-quality, good value products cited as reason for pharma reputation rise

The pharma industry’s corporate reputation internationally has risen by 10% since 2012 because of its ability to produce effective products at good prices, according to patient groups.

These 1,072 groups, based in 72 different countries, took part in a survey run between November 2015 and January this year by UK-based research organisation PatientView.

The report provides feedback on the corporate reputation, the extent to which companies are meeting the expectations of patients, using six indicators.